Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has announced the launch of its Hantavirus Research Reagents and Products to support hantavirus research and diagnostic assay development. This new catalog aims to assist academic researchers, biopharmaceutical companies, and industrial organizations in accelerating the development of diagnostic assays and therapeutic interventions targeting orthohantaviruses, which are dangerous rodent-borne pathogens.
Hantaviruses, classified as Category A pathogens by the US Centers for Disease Control and Prevention (CDC), are emerging zoonotic pathogens from the Bunyaviridae family. They pose a serious threat to human health, causing haemorrhagic fever with renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome (HCPS), both of which have high fatality rates. Transmission to humans occurs via aerosols containing excreta from infected rodent hosts.
The viruses have a tripartite negative-strand RNA genome, with three genomic RNA segments (S, M, and L) encoding the nucleocapsid protein (N), a precursor glycoprotein (which forms envelope glycoproteins Gn and Gc upon processing), and the viral RNA-dependent RNA polymerase (RdRp). The N protein is the primary structural component, protecting and encapsulating the genomic RNA strands. Recent studies indicate that the N protein works with RdRp in viral genome transcription and replication, and preferentially promotes viral mRNA translation.
Currently, no antiviral therapies or vaccines are available for hantavirus-associated diseases. A deeper understanding of the molecular mechanisms of the hantavirus life cycle could identify targets for antiviral therapy and drug design. Given the high case-fatality rates, developing an effective vaccine is imperative. Early clinical manifestations of hantavirus infection often resemble common respiratory or influenza-like illnesses, underscoring the urgent need for highly sensitive, reliable, and standardized laboratory diagnostic tools for early differential diagnosis and accurate target validation.
To address these research challenges, Creative Diagnostics offers a range of hantavirus research reagents covering multiple strains, including Hantavirus, Puumala virus (PUUV), Seoul virus (SEOV), and Sin Nombre virus (SNV). The new product line includes: recombinant hantavirus antigens for assay development; high-affinity monoclonal and polyclonal antibodies validated for capture and detection across multiple platforms such as Western blot, flow cytometry, immunohistochemistry, and surface plasmon resonance; and supporting reagents for ELISA and rapid immunoassay research.
For detailed product specifications, volume pricing, or to browse the complete list of available viral solutions, visit the official product portal at https://www.creative-diagnostics.com/hantavirus.htm.
